publication date: Oct. 1, 2014
html NCI CTEP.html
NCI CTEP-Approved Trials for the Month of September
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
9605: Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas. National Cancer Institute Developmental Therapeutics Clinic; Kummar, Shivaani. (301) 435-0517
AMC-091: Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma. AIDS-Associated Malignancies Clinical Trials Consortium; Kasamon, Yvette L. (410) 955-8839
AOST1322: A Phase II Study of Eribulin (IND# 122686, NSC# 707389) in Recurrent or Refractory Osteosarcoma. Children’s Oncology Group; Isakoff, Michael Scott. (860) 545-9630
A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). Alliance for Clinical Trials in Oncology; Govindan, Ramaswamy. (314) 362-5737
A221304: A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy. Alliance for Clinical Trials in Oncology; Miller, Robert C. (507) 284-2669
NRG-GI001: Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma. NRG Oncology; Hong, Theodore Sunki. (617) 726-5866
9671: … Continue reading CCL Sept – NCI CTEP
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.